Patents by Inventor David S. Baker

David S. Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240334578
    Abstract: A load control system may include control devices capable of being associated with each other at one or more locations for performing load control. Control devices may include control-source devices and/or control-target devices. A location beacon may be discovered and a unique identifier in the location beacon may be associated with a unique identifier of one or more control devices. Upon subsequent discovery of the location beacon, the associated load control devices may be controlled. The beacons may be communicated via radio frequency signals, visible light communication, and/or audio signals. The visible light communication may be used to communicate other types of information to devices in the load control system. The visible light communication may be used to identify link addresses for communicating with load control devices, load control instructions, load control configuration instructions, network communication information, and/or the like.
    Type: Application
    Filed: June 10, 2024
    Publication date: October 3, 2024
    Applicant: Lutron Technology Company LLC
    Inventors: Rhodes B. Baker, Kyle Thomas Barco, Bryan Robert Barnes, John H. Bull, Richard S. Camden, Jordan H. Crafts, David J. Dolan, Jason Groller, Sanjeev Kumar, Jonathan T. Lenz, Miguel Aguado Pelaez, Daniel L. Twaddell
  • Patent number: 12070466
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: August 27, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20240165098
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: December 14, 2023
    Publication date: May 23, 2024
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20240139166
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition comprises a low concentration of an ophthalmic agent for treatment of presbyopia. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 2, 2024
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Patent number: 11896588
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: February 13, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 11890277
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: February 6, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 11883390
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: January 30, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20230381016
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 1, 2023
    Publication date: November 30, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20230091109
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20230092957
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20230093205
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Patent number: 11596625
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 7, 2023
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20230041788
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Further disclosed herein is an ophthalmic including a low concentration of an ophthalmic agent and various ratios of water to deuterated water.
    Type: Application
    Filed: December 15, 2020
    Publication date: February 9, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20220409603
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220409605
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220409604
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220378775
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 25, 2022
    Publication date: December 1, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220265632
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 25, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220265631
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 25, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Patent number: 11382909
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: July 12, 2022
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri